---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-273953"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:13:49.727218+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports 100% AML CR rate with INB-100 at ASH; no relapses after median 19.7 months

## Summary
- 100% of AML patients (n=10) remain in complete remission after median 19.7 months follow-up; no relapses or new deaths as of Sept 30, 2024.
- INB-100 shows durable in vivo expansion and persistence of allogeneic gamma-delta T cells at 365 days post single dose.
- No CRS, neurotoxicity (ICANS), or dose-limiting toxicities observed; low-grade GvHD steroid-responsive in 60% of patients.
- Expansion cohort enrollment ongoing at DL2 (RP2D); updated data expected first half 2025.
- Three patients in CR >3 years, one progression-free >4 years.

## SEC filing metadata
- accession: 0001193125-24-273953
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312524273953/0001193125-24-273953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312524273953/d888773d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-273953
- JSON: https://secwatch.observer/filing/0001193125-24-273953.json
- Plain text: https://secwatch.observer/filing/0001193125-24-273953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.